BRCA2 and neoplasm: It seems likely that the sensitivity of BRCA defective tumour cells to PARP inhibitors is caused by their characteristic defect in repair of DNA double strand breaks (DSBs) by homologous recombination (HR), a process controlled by BRCA1, BRCA2 and the DNA recombinase RAD51 [3].